Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
LifeLink Foundation Names Kelly Cullen COO
LifeLink Foundation announced that Kelly Cullen, RN, MBA, has joined the organization as Chief Operating Officer to support its mission and ongoing growth. In her new role, Cullen will provide strategic and operational leadership, strengthen team engagement and development, and enhance the foundation’s impact on patients, families, and communities served. She brings more than 30 years of experience across clinical care, operations, and executive leadership, including extensive work in healthcare administration.
Genentech Reports Positive Phase III Results for Gazyva
Genentech, part of the Roche Group, announced that the Phase III MAJESTY study in adults with primary membranous nephropathy successfully met its primary endpoint, demonstrating statistically significant and clinically meaningful results with Gazyva (obinutuzumab). The trial showed that a significantly higher number of patients achieved complete remission at 104 weeks compared with those treated with tacrolimus. The safety profile of Gazyva was consistent with previous studies, and no new safety concerns were identified.
Europe Oncology Genomics Report by DeciBio
DeciBio Consulting LLC has introduced a new Europe Oncology Genomics Tracker that sheds light on how genomic technologies are being assessed and integrated into solid tumor care across the five largest European markets, including France, Germany, Italy, Spain, and the United Kingdom. Built on feedback from more than one hundred medical oncologists, the report offers a detailed snapshot of how clinicians are approaching genomic testing in daily practice. It explores where adoption is accelerating, where barriers remain, and how priorities differ across healthcare systems in the region.
VB Spine to Acquire Rights to Augmedics Spine Platform
VB Spine LLC, recognized as the largest privately held spine-focused company, has signed a definitive agreement to secure exclusive rights to the xvision Spine System from Augmedics. The addition of this augmented reality navigation platform strengthens VB Spine’s expanding visualization portfolio and signals a significant step forward in its technology strategy. Augmedics made history as the first company to receive FDA clearance for an augmented reality navigation system designed specifically for spine surgery. With this agreement, VB Spine aims to position itself at the forefront of AR-driven spine innovation. The deal remains subject to regulatory approval and standard closing requirements and is anticipated to be finalized in the coming weeks.
Worldwide Clinical Trials Acquires Catalyst Clinical Research
Worldwide Clinical Trials, a leading global contract research organization, has finalized its acquisition of Catalyst Clinical Research LLC, a specialized oncology CRO and functional service provider. This strategic combination brings together two organizations with complementary strengths in oncology, biometrics, and FSP solutions, significantly enhancing Worldwide’s ability to serve biopharma clients across the globe. The merger expands Worldwide’s workforce to approximately 4,400 employees in over 70 countries, creating a stronger, more versatile clinical research platform.
To share your insights, please write to us at sudipto@intentamplify.com
